Abstract
The World Asthma Phenotypes (WASP) study is being conducted in five centres in Brazil, Ecuador, Uganda, New Zealand and the United Kingdom, with a range of prevalence levels and exposures, and a likely range of phenotype distributions. Here we present the main findings with regards to asthma inflammatory phenotypes. We recruited 998 cases and 356 controls: 204/40 in Brazil, 176/67 in Ecuador, 207/50 in Uganda, 235/132 in New Zealand, and 176/67 in the United Kingdom. All centres studied children and adolescents (age-range 8–20 years), with the exception of the UK centre which involved 26–27 year olds. The proportion of participants who produced sputum samples was 87%, with a range from 74% (Brazil) to 91% (Ecuador), and of these 62% were countable with regards to the inflammatory cell types.The proportions of asthma cases who were classified as eosinophilic or mixed granulocytic asthma (the two inflammatory phenotypes which involve eosinophilia) was 39% overall: 35% in Brazil, 32% in Ecuador, 33% in Uganda, 50% in New Zealand, and 28% in the United Kingdom. The non-eosinophilic asthmatics (NEA) had similar chronic severity (e.g. in terms of attacks in the previous year) to the eosinophilic asthmatics (EA). Of the 61% of cases with NEA, 50% showed no signs of inflammation (paucigranulocytic), with 11% having neutrophilic inflammation. This is the first time that sputum induction has been used in a standardised manner to compare asthma inflammatory phenotypes in high income countries (HICs) and low-and-middle-income countries (LMICs). It confirms that most cases are non-eosinophilic, with the proportions ranging from 50% to 72%, across these varied environments; most of these non-eosinophilic cases were paucigranulocytic, with no sign of airways inflammation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The World ASthma Phenotypes (WASP) collaboration is based on the AsthmaPhenotypes study which is funded by the European Research Council under the European Union Seventh Framework Programme (FP7/2007-2013) / ERC grant agreement no 668954. ALSPAC: We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. Alison Elliott and Philip Cooper were funded by Wellcome Trust grant numbers 095778 and 088862, respectively.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
London School of Hygiene and Tropical Medicine Research Ethics Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is currently not available. We will consider requests for data sharing after the main findings have been published.
